Animal experimentation is both controversial and unreliable in providing human-relevant results.
But traditional 2D cell culture of human cells fails to capture the complexity of the 3D cellular microenvironment.
3D tissue engineering is the answer. Frontier Bio is leading the way.
IN PARTNERSHIP WITH:
ENGINEERED BLOOD VESSELS
Replacing Animals in Vascular Research
Made of living human cells, our vascular Blood Vessel Mimics (BVMs) are already being used for medical device testing. Contact us to apply our tech to your application.
Improving Vascular Surgery Outcomes
Tissue-engineered vascular grafts are a potentially superior solution for vascular surgeons for Peripheral Artery Disease, Trauma, Cardiac Bypass, and Reconstructive surgery. They can be made using the patient's own cells and can lower risk of rejection. Frontier Bio's goal is to make this a reality.
Emulating the Brain Like Never Before
Organ-on-a-Chip technology is a promising tool for translatable in vitro testing. However, the complexity of the brain and how it interacts with the blood-brain-barrier (BBB) remains a challenge. Our NVU-on-a-Chip is a powerful tool that models the fundamental building block in the brain - the Neuro-Vascular Unit. No other chip creates a membrane-free, continuous, intact BBB that can be imaged with a standard fluorescent microscope.
Towards Eradicating Neurological Illnesses
Our chip has been used to screen stem cell therapies for ischaemic stroke. We partner with academia and industry to tackle the major neurological illnesses facing people today like Alzheimer's Disease, Epilepsy, Parkinson's, and beyond.
Modeling Human Tissues & Diseases
Organoids are miniature, 3D structures that mimic the organization and functions of organs in the body. We create and apply vascularized organoids (and similar constructs) towards drug development, disease modeling, and personalized medicine.
Enhanced with Bioprinting
We combine powerful tissue engineering techniques such as organoids, bioprinting, & microfluidics for various projects.
FDA MODERNIZATION ACT 2.0
"The FDA Modernization Act 2.0, signed by President Biden, allows clinical trial leaders to use animal trial alternatives instead of traditional animal modeling for drug and biological development."
- Veronica Salib, Pharma News Intelligence